Medical costs go up as a result of surgical site infections (SSIs). Women with COVID-19 infection are more susceptible to infection. Maxipime and Unictam have been evaluated to determine how well they prevented post-cesarean SSIs in pregnant COVID-19 carriers. On the day of surgery, 100 cases received either Maxipime or Unictam treatment. Two groups of patients were created: Group 1 included 50 patients taking Maxipime, and Group 2 included 50 patients taking Unictam. For two weeks, the patients underwent daily SSI following up. Infections at the surgical site occurred at a rate of 21.4% in group 1 and 28.6% in group 2. In 33% of the positive cultures in group 1 and 25% in group 2, Pseudomonas was isolated. Staph-aureus was isolated in 67% of the positive cultures in group 1 and 75% in group 2. By comparing the rates of post-cesarean surgical site infections after using Maxipime or Unictam in COVID-19 cases, we found an increase in the SSI rate in group2 more than in group1. Compared to women without COVID-19 infection, women with COVID-19 infection had a higher rate of post-cesarean SSI. In COVID-19 cases, we advise using Maxipime to prevent SSI following a caesarean delivery. This is due to the fact that Maxipime has a dual action as an antiviral effect besides an antibacterial effect against various types of bacteria.